Jack Allen
Stock Analyst at Baird
(1.52)
# 3,515
Out of 5,147 analysts
43
Total ratings
41.18%
Success rate
-8.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACLX Arcellx | Downgrades: Neutral | $106 → $115 | $113.79 | +1.06% | 6 | Feb 23, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $52 → $44 | $60.14 | -26.84% | 3 | Nov 11, 2025 | |
| VOR Vor Biopharma | Upgrades: Outperform | $20 → $64 | $15.44 | +314.51% | 5 | Oct 15, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Outperform | $7 → $12 | $4.53 | +164.90% | 5 | Oct 2, 2025 | |
| FATE Fate Therapeutics | Maintains: Neutral | $5 → $4 | $1.48 | +170.27% | 2 | May 14, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $12 → $9 | $2.78 | +223.74% | 3 | May 14, 2025 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $80 → $40 | $10.95 | +265.30% | 2 | Nov 15, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $24 → $18 | $13.78 | +30.62% | 2 | Oct 25, 2024 | |
| TIL Instil Bio | Reiterates: Outperform | $180 | $8.90 | +1,922.47% | 9 | Sep 16, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $0.37 | +2,058.66% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $84 | $32.30 | +160.06% | 1 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $1.92 | +160.42% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.88 | - | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $9 | $4.10 | +119.51% | 1 | Oct 7, 2021 |
Arcellx
Feb 23, 2026
Downgrades: Neutral
Price Target: $106 → $115
Current: $113.79
Upside: +1.06%
CRISPR Therapeutics AG
Nov 11, 2025
Maintains: Neutral
Price Target: $52 → $44
Current: $60.14
Upside: -26.84%
Vor Biopharma
Oct 15, 2025
Upgrades: Outperform
Price Target: $20 → $64
Current: $15.44
Upside: +314.51%
Taysha Gene Therapies
Oct 2, 2025
Maintains: Outperform
Price Target: $7 → $12
Current: $4.53
Upside: +164.90%
Fate Therapeutics
May 14, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $1.48
Upside: +170.27%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $12 → $9
Current: $2.78
Upside: +223.74%
MiNK Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $80 → $40
Current: $10.95
Upside: +265.30%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $24 → $18
Current: $13.78
Upside: +30.62%
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $8.90
Upside: +1,922.47%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $0.37
Upside: +2,058.66%
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $32.30
Upside: +160.06%
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $1.92
Upside: +160.42%
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $3.88
Upside: -
Oct 7, 2021
Upgrades: Outperform
Price Target: $6 → $9
Current: $4.10
Upside: +119.51%